References More than a third of patients on Wegovy pill are new to GLP-1 drugs, study finds, Reuters, 11 February 2026 (study by health data firm Truveta, among early users of Novo Nordisks Wegovy weight-loss pill): IQVIA Market Analysis, 5 January 2026: GLP-1 receptor agonists and dual GLP-1/GIP receptor agonists: strengthened warnings on acute pancreatitis, including necrotising and fatal cases, UK MHRA, 29 January 2026: PRAC concludes eye condition NAION is a very rare side effect of semaglutide medicines Ozempic, Rybelsus and Wegovy, European Medicines Agency, 6 June 2025: Microdosing: how off-label use of weight loss jabs is spreading from US to UK, The Guardian, July 2025: (see also Side effects of GLP-1 receptor agonists, British Medical Journal, August 2025: Exploring potential associations between GLP-1RAs and depressive disorders: a pharmacovigilance study based on FAERS and VigiBase data, The Lancet, August 2025: Subscribe to our e-Newsletters Stay up to date with the latest news, articles, and events
Pancreatitis: Report severe, persistent abdominal pain immediately Gallbladder disease: Rapid weight loss of any kind can increase gallstone risk Hypoglycemia: Uncommon when used alone
Filippatos, T
Heres what to expect: Treatments can be scheduled as standalone sessions or combined with other IV therapies for enhanced results
Conclusion L-Carnitine, a naturally occurring compound involved in energy metabolism, has shown promise as a therapeutic uses for various health conditions
